Atlas Architect

Decision Instrument

Program Setup

Objective Definition

Define therapeutic intent, constraints, and translational posture to produce a program brief that drives architecture selection.

Program inputs

Indication

Huntington's disease

Mechanistic objective

Widespread neuronal HTT silencing

Target organ

Central nervous system

Target cell type

Medium spiny neurons + cortical neurons

Tissue coverage requirement

High, bilateral broad CNS distribution

Payload class

miRNA expression cassette

Payload size

~3.2 kb

Desired expression duration

Multi-year

Administration route

Systemic IV preferred

Procedural burden tolerance

Moderate

Redosing requirement

Likely needed in lifecycle

Liver exposure tolerance

Low

Immune risk tolerance

Low-to-moderate

Translation priority

High

Cost sensitivity

Medium

Manufacturing tolerance

Conservative

Barrier/access challenge

Blood-brain barrier crossing

Barrier / access challenge options

Blood-brain barrier crossing
Retinal penetration
Inner ear access
Body-wide muscle distribution
Tumor-selective targeting
None / standard

Live Program Brief

Draft synced

Objective targets broad CNS neuronal silencing with durable expression under low liver exposure tolerance and high translation priority.

Program is constrained by BBB penetration, immunity, and manufacturability. Candidate architectures should maximize CNS:liver ratio and preserve repeat-dose optionality.